Xeris Biopharma Holdings, Inc.
XERS
$7.59
$0.020.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 246.03M | 222.55M | 203.07M | 187.36M | 181.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 246.03M | 222.55M | 203.07M | 187.36M | 181.41M |
| Cost of Revenue | 43.70M | 39.59M | 36.83M | 34.92M | 29.53M |
| Gross Profit | 202.33M | 182.96M | 166.24M | 152.44M | 151.88M |
| SG&A Expenses | 167.42M | 163.02M | 157.38M | 160.91M | 153.23M |
| Depreciation & Amortization | 10.84M | 10.84M | 10.84M | 10.84M | 10.84M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 249.75M | 238.94M | 230.62M | 232.53M | 218.60M |
| Operating Income | -3.72M | -16.39M | -27.55M | -45.17M | -37.19M |
| Income Before Tax | -35.32M | -47.65M | -57.10M | -65.62M | -59.08M |
| Income Tax Expenses | -3.32M | -2.58M | -2.27M | -2.50M | 482.00K |
| Earnings from Continuing Operations | -32.00 | -45.08 | -54.84 | -63.11 | -59.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.00M | -45.08M | -54.84M | -63.11M | -59.56M |
| EBIT | -3.72M | -16.39M | -27.55M | -45.17M | -37.19M |
| EBITDA | 8.38M | -4.33M | -15.48M | -33.06M | -25.00M |
| EPS Basic | -0.21 | -0.30 | -0.38 | -0.44 | -0.42 |
| Normalized Basic EPS | -0.12 | -0.18 | -0.23 | -0.30 | -0.27 |
| EPS Diluted | -0.21 | -0.30 | -0.38 | -0.44 | -0.42 |
| Normalized Diluted EPS | -0.12 | -0.18 | -0.23 | -0.30 | -0.27 |
| Average Basic Shares Outstanding | 609.99M | 598.88M | 586.95M | 575.98M | 565.04M |
| Average Diluted Shares Outstanding | 609.99M | 598.88M | 586.95M | 575.98M | 565.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |